Stokes Family Office LLC Sells 1,749 Shares of Novo Nordisk A/S (NYSE:NVO)

Stokes Family Office LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 18.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,975 shares of the company’s stock after selling 1,749 shares during the quarter. Stokes Family Office LLC’s holdings in Novo Nordisk A/S were worth $825,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clarius Group LLC increased its stake in Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC grew its stake in Novo Nordisk A/S by 2.0% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after acquiring an additional 95 shares in the last quarter. 9258 Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 4.0% during the fourth quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after acquiring an additional 97 shares during the period. Relyea Zuckerberg Hanson LLC raised its stake in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock valued at $327,000 after acquiring an additional 99 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its stake in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock valued at $306,000 after acquiring an additional 100 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. BMO Capital Markets started coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Down 0.8 %

Shares of NYSE:NVO traded down $0.97 during trading on Friday, reaching $123.05. The stock had a trading volume of 5,932,926 shares, compared to its average volume of 3,905,318. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $552.19 billion, a P/E ratio of 42.44, a PEG ratio of 2.07 and a beta of 0.43. The firm’s 50-day simple moving average is $127.21 and its 200 day simple moving average is $112.77. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. The business had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.